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Summary
Background The hospital environment is a source of pathogen transmission. The effect of enhanced disinfection 
strategies on the hospital-wide incidence of infection has not been investigated in a multicentre, randomised 
controlled trial. We aimed to assess the effectiveness of four disinfection strategies on hospital-wide incidence of 
multidrug-resistant organisms and Clostridium difficile in  the Benefits of Enh anced Ter minal Roo m (BETR) 
Disinfection study.
Methods We did a prespecified secondary analysis of the results from the BETR Disinfection study, a pragmatic, 
multicentre, crossover cluster-randomised trial that assessed four different strategies for terminal room disinfection 
in nine hospitals in the southeastern USA. Rooms from which a patient with a specific infection or colonisation (due 
to the target organisms C difficile, meticillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci (VRE), 
or multidrug-resistant Acinetobacter spp) was discharged were terminally disinfected with one of four strategies: 
standard disinfection (quaternary ammonium disinfectant, except for C difficile, for which 10% hypochlorite [bleach] 
was used; reference); standard disinfection and disinfecting ultraviolet light (UV-C), except for C difficile, for which 
bleach and UV-C was used (UV strategy); 10% hypochlorite (bleach strategy); and bleach and UV-C (bleach and UV 
strategy). We randomly assigned the sequence of strategies for each hospital (1:1:1:1), and each strategy was used for 
7 months, including a 1-month wash-in period and 6 months of data collection. The prespecified secondary outcomes 
were hospital-wide, hospital-acquired incidence of all target organisms (calculated as number of patients with 
hospital-acquired infection with a target organism per 10 000 patient days), and hospital-wide, hospital-acquired 
incidence of each target organism separately. BETR Disinfection is registered with ClinicalTrials.gov, number 
NCT01579370.
Findings Between April, 2012, and July, 2014, there were 271 740 unique patients with 375 918 admissions. 
314 610 admissions met all inclusion criteria (n=73 071 in the reference study period, n=81 621 in the UV study period, 
n=78 760 in the bleach study period, and n=81 158 in the bleach and UV study period). 2681 incidenct cases of hospital-
acquired infection or colonisation occurred during the study. There was no significant difference in the hospital-wide 
risk of target organism acquisition between standard disinfection and the three enhanced terminal disinfection 
strategies for all target multidrug-resistant organisms (UV study period relative risk [RR] 0·89, 95% CI 0·79–1·00; 
p=0·052; bleach study period 0·92, 0·79–1·08; p=0·32; bleach and UV study period 0·99, 0·89–1·11; p=0·89). The 
decrease in risk in the UV study period was driven by decreases in risk of acquisition of C difficile (RR 0∙89, 95% CI 
0∙80–0∙99; p=0∙031) and VRE (0∙56, 0∙31–0∙996; p=0∙048). 
Interpretation Enhanced terminal room disinfection with UV in a targeted subset of high-risk rooms led to a decrease 
in hospital-wide incidence of C difficile and VRE. Enhanced disinfection overcomes limitations of standard disinfection 
strategies and is a potential strategy to reduce the risk of acquisition of multidrug-resistant organisms and C difficile.
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Health-care-associated infections kill 75 000 patients 
each year in the USA.1 Multidrug-resistant organisms are 
common causes of these infections, with Clostridium 
difficile being the most common cause.2 Health-care-
associated infections lead to adverse patient outcomes, 
including increased duration of hospital stay, morbidity, 
and mortality.3–5
The hospital environment is a source of pathogen 
transmission due to routine contamination with 
pathogens that can survive on inanimate surfaces for 
days or months.6–8 Standard terminal disinfection, 
defined as the disinfection of a room after a patient’s 
departure to prepare the room for a new occupant, does 
not sufficiently eliminate contamination.9 Consequently, 
patients admitted to rooms previously occupied by 
patients with multidrug-resistant organisms or C difficile 
(so-called high-risk rooms) are at a substantially 
increased risk of subsequent infection or colonisation.10–13
In 2017, we reported the results of the Benefits of 
Enhanced Terminal Room (BETR) Disinfection study, 
the first multicentre randomised controlled trial to 
investigate strategies for enhanced terminal room 
disinfection.14 The results of this trial showed that adding 
ultraviolet light (UV-C) disinfection to standard chemical 
terminal disinfection of high-risk rooms led to a 
significant decrease in the risk of acquisition and 
infection with multidrug-resistant organisms and 
C difficile for patients admitted to these rooms.
However, infectious outcomes in patients admitted to 
hospital are not independent; patient-level assessments 
will not fully capture the effect of enhanced disinfection 
strategies on the incidence of infections among all 
patients admitted to hospital. We aimed to assess the 
effect of the three enhanced terminal disinfection 
strategies investigated during the BETR Disinfection 
study on the hospital-wide incidence of C difficile, 
meticillin-resistant Staphylococcus aureus (MRSA), vanco-
mycin-resistant enterococci (VRE), and multidrug-
resistant Acinetobacter spp.
Methods
Study design and participants
We did a prespecified secondary analysis of the BETR 
Disinfection study,14 a pragmatic, prospective, multi-
centre, cluster-randomised trial with crossover design 
that assessed four different strategies for terminal room 
disinfection.
This study was designed to detect hospital-wide 
infection or colonisation due to one of four so-called 
target organisms: C difficile, MRSA, VRE, or multidrug-
resistant Acinetobacter spp.15 We defined a history of 
infection or colonisation as any positive culture with a 
target organism within 12 months of admission. We 
defined community-onset infection as the isolation of a 
target organism within the first 48 h of hospital 
admission. We defined hospital-acquired as the isolation 
of a target organism after 48 h of hospitalisation. We 
defined a seed room as a room housing a patient with a 
microbiologically-proven current or past history of 
infection or colonisation with one or more target 
organisms.
In this study, we considered all patients admitted to a 
study hospital during the BETR study period (April, 2012, 
to July, 2014). Patients were included in the analysis if 
they were in the hospital for at least 48 h. An incident 
case occurred during a hospital admission if the patient 
had a positive clinical culture or test with one of the 
target organisms. Patients were excluded if they had a 
microbiologically proven history of infection or 
colonisation with the same target organism during the 
12 months previous to hospital admission, or had a 
community-onset infection.
Research in context
Evidence before this study
The hospital environment can be contaminated with 
multidrug-resistant organisms and is often disinfected 
inadequately. As a result, patients who enter contaminated 
hospital rooms are at increased risk for acquisition and 
infection with these multidrug-resistant organisms. Enhanced 
disinfection strategies might decrease the risk of transmission 
of multidrug-resistant organisms through the hospital 
environment, but supportive evidence is limited to 
single-centre, quasi-experimental studies. We searched 
PubMed using the terms “terminal disinfection” and “UV 
disinfection” to identify results of clinical studies published 
between Jan 1, 2003, and Jan 31, 2018. We identified 
13 relevant studies, which were included in a meta-analysis 
that showed that UV disinfection was most effective at 
decreasing incidence of hospital-acquired Clostridium difficile 
and vancomycin-resistant enterococci (VRE). However, all but 
one of these studies were done in single institutions, with 
quasi-experimental study design, multiple interventions, and 
no appropriate controls.
Added value of this study
To the best of our knowledge, this is the first multicentre, 
randomised controlled trial to investigate the effect of 
enhanced disinfection strategies on the hospital-wide incidence 
of hospital-acquired infections caused by four target 
multidrug-resistant organisms: C difficile, meticillin-resistant 
Staphylococcus aureus (MRSA), VRE, and multidrug-resistant 
Acinetobacter spp. The addition of a UV-C device to standard 
terminal room disinfection decreased the risk of subsequent 
acquisition and infection by target multidrug-resistant 
organisms such as C difficile and VRE. This study further shows 
that enhanced disinfection can have both a direct effect on the 
next patient who enters a contact isolation room and an 
indirect beneficial effect on other patients admitted to hospital.
Implications of all the available evidence
Infections with multidrug-resistant organisms lead to adverse 
outcomes. Novel prevention strategies are needed. Enhanced 
disinfection is a potential strategy to reduce the risk of acquisition 
of multidrug-resistant organisms, through both direct (for MRSA 
and VRE) and indirect effects (C difficile and VRE). 
We considered all microbiological cultures for 
inclusion in our outcome analysis. Cultures could have 
been representative of infection or colonisation. We did 
not specifically obtain screening cultures for this study. 
All hospitals used nucleic acid amplification tests to 
identify C difficile throughout the study.
The Duke University Health System institutional 
review board served as the central institutional review 
board. All participating hospitals received a waiver of 
informed consent and approval from their local 
institutional review boards.
Randomisation and masking
Each strategy was used at each study hospital during four 
sequential 7-month study periods. The sequence of 
strategies was randomly selected for each hospital, as 
described elsewhere.14 Each study period included a 
1-month wash-in period, followed by a 6-month period of
data collection. All hospitals used all four strategies in a
1:1:1:1 ratio. Allocation was not masked.
Procedures
All study hospitals employed gown and glove precautions 
(ie, contact precautions) for patients known or suspected 
to have colonisation or infection with target organisms. 
For the purpose of this study, these contact precaution 
rooms were defined as targeted rooms. Four strategies 
for terminal room disinfection were employed in targeted 
rooms. Strategy A, the reference period, involved the use 
of a quaternary ammonium-containing disinfectant 
(EnCompass Quaternary Disinfectant Cleaner and the 
EnCompass System, Ecolab, St Paul, MN, USA) in all 
targeted rooms except rooms of patients with C difficile, 
in which a 10% hypochlorite-containing disinfectant 
(bleach; Clorox Germicidal Wipes, Clorox, Oakland, CA, 
USA) was used. Strategy B involved the use of a 
quaternary ammonium-containing disinfectant and a 
UV-C device in all targeted rooms except rooms of 
patients with C difficile, in which a bleach-containing 
disinfectant and UV-C device were used. Strategy C 
involved the use of a bleach-containing disinfectant in all 
targeted rooms. Strategy D involved the use of a bleach-
containing disinfectant and a UV-C device for all targeted 
rooms. For ease of discussion, these four strategies will 
be labelled hereafter as reference (strategy A), UV 
(strategy B), bleach (strategy C), and bleach and UV 
(strategy D). All other rooms were considered to be non-
targeted, and strategy A was used for terminal 
disinfection in non-targeted rooms throughout the study. 
Chemical disinfectants were standardised across study 
hospitals.14
Outcomes
There were two prespecified secondary outcomes: 
hospital-wide, hospital-acquired incidence of all target 
organisms, and hospital-wide, hospital-acquired incidence 
of each target organism separately. We calculated 
hospital-wide incidence as the number of patients with 
hospital-acquired outcomes with a target organism per 
10 000 patient days among eligible patients.
Statistical analysis
Our a-priori hypothesis was that use of enhanced 
terminal disinfection in targeted rooms would lead to 
Figure 1: Trial profile for hospital-wide analysis of Benefits of Enhanced Terminal Room Disinfection study
271 740 patients with 375 918 admissions
 in nine hospitals
45 282 admissions during 
wash-in periods
85 492 admissions in 
 bleach and UV group
82 837 admissions in 
 bleach group
3848 excluded
49 cultures <48 h 
from admission
1842 community onset
1957 previous history 
85 469 admissions 
in UV group
3767 excluded
67 cultures <48 h 
from admission
1645 community onset
2055 previous history 
76 838 admissions in 
reference group
2681 outcomes for analysis 
78 760 eligible admissions 
 for analysis
81 158 eligible admissions 
 for analysis
81 621 eligible admissions 
for analysis
73 071 eligible admissions 
for analysis
4077 excluded
56 cultures <48 h 
from admission
1882 community onset
2139 previous history 
4334 excluded
55 cultures <48 h 
from admission
1934 community onset
2345 previous history 
decreases in the risk of hospital-wide, hospital-acquired 
target organisms for the hospital population. In other 
words, enhanced terminal room cleaning strategies in 
targeted rooms would have both direct and indirect 
effects, leading to decreased risk of acquisition of target 
organisms among all hospitalised patients.
We analysed incidence using overdispersed Poisson 
models, with disinfection strategy (reference, UV, 
bleach, and bleach and UV), order of the strategies 
within the study (whether a particular strategy was used 
in study period one, two, three, or four), and hospital as 
fixed-effect categorical covariates. We used generalised 
estimating equations to account for correlation between 
different study periods within the same hospital. 
Outcomes of patients admitted to hospital during each 
intervention were compared with the reference study 
period. The same model construction strategy was used 
for all outcomes. For each outcome, we calculated 
relative risk (RR), risk differences, and 95% CIs. 
Statistical tests were done at a two-sided significance 
level of 0·05. We did no formal adjustments for multiple 
comparisons.
We also did a post-hoc analysis, to better assess if 
patients could receive indirect benefit from the use of UV 
for terminal disinfection. All study patients were 
separated into four categories, on the basis of the type of 
room entered and terminal room disinfection strategy 
used: (1) room cleaned with chemical disinfectants only 
and did not enter a confirmed seed room; (2) room 
cleaned with chemical disinfectants only and entered a 
Standard disinfection period 
(reference group)
UV period Bleach period Bleach and UV period
All target organisms
Exposed admissions 73 071 81 621 78 760 81 158
Incident cases (%) 626 (0∙86%) 683 (0∙84%) 671 (0∙85%) 701 (0∙86%)
Patient days 345 484 397 222 382 388 401 822
Incidence (per 10 000 patient days) 18∙1 17∙2 17∙5 17∙4
Risk difference (95% CI) 1 (ref) 0∙93 (–0∙83 to 2∙68) 0∙57 (–1∙21 to 2∙35) 0∙67 (–1∙12 to 2∙46)
Relative risk (95% CI); p value 1 (ref) 0∙89 (0∙79 to 1∙00); 0∙052 0∙92 (0∙79 to 1∙08); 0∙32 0∙99 (0∙89 to 1∙11); 0∙89
Clostridium difficile
Exposed admissions 76 099 84 776 82 193 84 741
Incident cases (%) 375 (0∙49%) 389 (0∙46%) 362 (0∙44%) 389 (0∙46%)
Patient days 372 654 426 157 411 471 436 330
Incidence (per 10 000 patient days) 10∙1 9∙13 8∙80 8∙92
Risk difference (95% CI) 1 (ref) 0∙93 (–0∙31 to 2∙18) 1∙27 (0∙005 to 2∙53) 1∙15 (–0∙13 to 2∙43)
Relative risk (95% CI); p value 1 (ref) 0∙89 (0∙80 to 0∙99); 0∙031 0∙91 (0∙75 to 1∙10); 0∙32 0∙97 (0∙84 to 1∙12); 0∙68
Meticillin-resistant Staphylococcus aureus
Exposed admissions 74 273 82 773 80 008 82 576
Incident cases (%) 204 (0∙27%) 259 (0∙31%) 234 (0∙29%) 242 (0∙29%)
Patient days 360 268 411 857 397 959 420 338
Incidence (per 10 000 patient days) 5∙66 6∙29 5∙88 5∙76
Risk difference (95% CI) 1 (ref) –0∙63 (–1∙63 to 0∙37) –0∙22 (–1∙21 to 0∙77) –0∙10 (–1∙08 to 0∙89)
Relative risk (95% CI); p value 1 (ref) 1∙08 (0∙89 to 1∙30); 0∙42 0∙97 (0∙76 to 1∙24); 0∙82 1∙00 (0∙87 to 1∙14); 0∙97
Vancomycin-resistant enterococci
Exposed admissions 76 125 84 733 81 910 84 466
Incident cases (%) 121 (0∙16%) 138 (0∙16%) 189 (0∙23%) 194 (0∙23%)
Patient days 373 306 427 099 409 366 432 599
Incidence (per 10 000 patient days) 3∙24 3∙23 4∙62 4∙48
Risk difference (95% CI) 1 (ref) 0∙010 (–0∙77 to 0∙79) –1∙38 (–2∙21 to –0∙54) –1∙24 (–2∙06 to –0∙42)
Relative risk (95% CI); p value 1 (ref) 0∙56 (0∙31 to0∙996); 0∙048 0∙87 (0∙65 to 1∙17); 0∙35 1∙28 (0∙94 to 1∙73); 0∙11
Multidrug-resistant Acinetobacter spp*
Exposed admissions 62 773 71 840 68 486 70 249
Incident cases (%) 6 (0∙01%) 3 (0∙00%) 4 (0∙01%) 3 (0∙00%)
Patient days 331 711 382 680 365 424 388 748
Rate (per 10 000 patient days) 0∙18 0∙08 0∙11 0∙08
Risk difference (95% CI) 1 (ref) 0∙10 (–0∙07 to 0∙28) 0∙07 (–0∙12 to 0∙26) 0∙10 (–0∙07 to 0∙28)
*No models were created for multidrug-resistant Acinetobacter baumanii given the few numbers of outcomes observed in each study group; one hospital was excluded because of missing data.
Table 1: Incidence of hospital acquisition of target multidrug-resistant organisms 
confirmed seed room; (3) room cleaned with UV and did 
not enter a confirmed seed room; and (4) room cleaned 
with UV and entered a confirmed seed room.
We calculated incidence of each target pathogen in 
each category. We hypothesised that the use of UV in 
the subset of targeted rooms (categories 3 and 4) 
would lead to improved outcomes for other hospitalised 
patients (categories 1 and 2). We tested this hypothesis by 
comparing incidence among patients who did not enter a 
room disinfected with UV across study periods. We did 
not do statistical testing because of the post-hoc nature of 
this analysis.
Power estimates were based on review of 4 years of 
surveillance data from study hospitals and published 
literature. All power calculations were done with a 
two-sided 0·05 significance level. Our power calculation 
for this analysis was based on the following assumptions. 
After excluding the wash-in periods, we projected that 
1·96 million patient days of care would be provided at 
the nine study hospitals, thus we projected that 
approximately 491 200 patient days of care would occur 
for each 6-month study period. On the basis of data from 
our pre-existing surveillance databases, we projected 
that 959 outcomes due to the four target organisms 
would occur during the reference 6-month period, for a 
baseline incidence of health-care-associated infection of 
19·5 per 10 000 patient days. Under these assumptions, 
the study would have 60% power to detect a 10% decrease 
in the incidence rate, 92% power to detect a 15% decrease, 
and more than 99% power to detect a 20% decrease. We 
did the power analysis using simulation and it was 
based on a Poisson regression model with hospital-wide 
incidence rate as the outcome and study arm and 
hospital as the covariates. We did all statistical analyses 
using SAS (version 9.4).
BETR Disinfection is registered with ClinicalTrials.gov, 
number NCT01579370.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
All nine hospitals participated and were randomly 
assigned in the 28-month study from April, 2012, to 
July, 2014; none withdrew. A total of 271 740 unique 
patients had 375 918 admissions during the study 
(figure 1); 314 6 10 admissions met all study criteria. A 
total of 2681 incident cases occurred during the study 
(table 1). During the reference period, 626 patients had 
an outcome during 345 484 patient days (incidence 
18∙1 per 10 000 patient days). The median incidence of 
target organisms per hospital was 17∙0 per 10 000 patient 
days (range 9∙6–52∙4) in the reference study period.
Overall, there was no significant difference between 
standard disinfection and the three enhanced terminal 
disinfection strategies in the hospital-wide risk of target 
organism acquisition for all multidrug resistant organisms 
(table 1). The largest decrease in risk was in the UV study 
period (n=683) compared with the reference study period 
(n=626; incidence 17∙2 per 10 000 patient days vs 18∙1 per 
10 000 patient days; RR 0∙89, 95% CI 0∙79–1∙00; p=0∙052; 
table 1).The use of bleach in targeted rooms (n=671) did not 
significantly decrease risk, compared with standard 
disinfection (incidence 17∙5 per 10 000 patient days vs 
18∙1 per 10 000 patient days; 0∙92, 0∙79–1∙08; p=0∙32). 
Hospital-wide risk of target organism acquisition was 
similar in both the bleach and UV (n=701) and the 
reference study periods (17∙4 per 10 000 patient days vs 
18∙1 per 10 000 patient days; 0∙99, 0∙89–1∙11; p=0∙89).
The hospital-wide risk of C difficile was significantly lower 
in the UV study period (rate 9∙13 per 10 000 patient days vs 
10∙1 per 10 000 patient days; RR 0∙89, 95% CI 0∙80–0∙99; 
p=0∙031), but was not significantly lower in the bleach 
study period (8∙80 per 10 000 patient days; 0∙91, 95% CI 
0∙75–1∙10; p=0∙32) or bleach and UV study period 
(8∙92 per 10 000 patient days; 0∙97, 0∙84–1∙12; p=0∙68). 
The risk of MRSA was essentially unchanged in all study 
periods and increased in the UV study period (table 1). The 
Figure 2: Four categories of exposure for patients admitted during the BETR Disinfection study
(1) Room cleaned with chemical disinfectants only and patient did not enter a confirmed seed room. (2) Room 
cleaned with chemical disinfectants only and patient entered into a confirmed seed room. (3) Room cleaned with 
UV and patient did not enter a confirmed seed room. (4) Room cleaned with UV and patient entered into a 
confirmed seed room. All patients admitted to hospital are included within the dashed circle. The size of the circles 
approximates the relative proportions of each category. The orange circle represents confirmed seed rooms. The 
blue circle represents rooms in which ultraviolet light was used during terminal disinfection. 
3 4 2 1
risk of VRE was significantly lower in the UV study period 
than in the reference study period (incidence 3∙23 per 
10 000 patient days vs 3∙24 per 10 000 patient days; 
0∙56, 0∙31–0∙99; p=0∙048). The use of bleach led to a non-
significant decrease in the risk of VRE whereas the risk was 
higher than reference in the bleach and UV study period.
Admissions were grouped into four exposure categories 
for our post-hoc analysis (figure 2; table 2). Patients who 
entered rooms that were cleaned using standard 
disinfection strategies (exposure categories 1 and 2) had 
lower incidence of C difficile infection during UV study 
periods than in other study periods (table 3); 729 cases of 
hospital-acquired C difficile infection occurred during 
779 049 patient days in non-UV study periods (incidence 
9∙36 per 10 000 patient days) compared with 592 cases 
during 739 048 patient days in UV study periods 
(incidence 8∙01 per 10 000 patient days). Incidence of 
hospital-acquired C difficile was lower among patients in 
categories 1 and 2 during all three enhanced room 
disinfection strategies, compared with patients in 
categories 1 and 2 in the reference study period (table 3). 
Among patients not exposed to rooms cleaned with UV, 
patients admitted to seed rooms (category 2) had 
approximately double or higher the incidence of patients 
admitted to non-seed rooms (category 1) for MRSA and 
VRE, and for most exposure categories (table 3). The 
incidence of hospital-acquired VRE after admission to a 
VRE seed room was five-times to ten-times higher than the 
incidence for patients not admitted to a VRE seed room.
Discussion
For all target organisms, the use of enhanced terminal 
room disinfection strategies in targeted, high-risk rooms 
led to a non-significant hospital-wide decrease in the risk 
All patients in categories 1 and 2 Did not enter a seed room (category 1) Entered a seed room (category 2)
Clostridium difficile
Non-UV disinfection strategy groups 729/779 049; 9∙36 695/757 193; 9∙18 34/21 856; 15∙6
UV disinfection strategy groups 592/739 048; 8∙01 583/730 619; 7∙98 9/8429; 10∙7
Individual disinfection strategy groups
Reference 372/369 737; 10∙1 353/358 875; 9∙84 19/10 862; 17∙5
UV 303/370 199; 8∙18 296/365 100; 8∙11 7/5099; 13∙7
Bleach 357/409 312; 8∙72 342/398 318; 8∙59 15/10 994; 13∙6
Bleach and UV 289/368 849; 7∙83 287/365 519; 7∙85 2/3330; 6∙01
Meticillin-resistant Staphylococcus aureus
Non-UV disinfection strategy groups 434/753 385; 5∙76 365/690 566; 5∙29 69/62 819; 11∙0
UV disinfection strategy groups 394/716 204; 5∙50 360/687 624; 5∙24 34/28 580; 11∙9
Individual disinfection strategy groups
Reference 204/357 479; 5∙71 171/327 342; 5∙22 33/30 137; 11∙0
UV 208/358 995; 5∙79 191/344 721; 5∙54 17/14 274; 11∙9
Bleach 230/395 906; 5∙81 194/363 224; 5∙34 36/32 682; 11∙0
Bleach and UV 186/357 209; 5∙21 169/342 903; 4∙93 17/14 306; 11∙9
Vancomycin-resistant enterococci
Non-UV disinfection strategy groups 304/777 649; 3∙91 235/750 260; 3∙13 69/27 389; 25∙2
UV disinfection strategy groups 208/739 366; 2∙81 188/728 617; 2∙58 20/10 749; 18∙6
Individual disinfection strategy groups
Reference 119/370 344; 3∙21 96/358 867; 2∙68 23/11 477; 20∙0
UV 89/371 767; 2∙39 79/367 108; 2∙15 10/4659; 21∙5
Bleach 185/407 305; 4∙54 139/391 393; 3∙55 46/15 912; 28∙9
Bleach and UV 119/367 599; 3∙24 109/361 509; 3∙02 10/6090; 16∙4
Data are number of patients per number of patient days; incidence per 10 000 patient days. UV=ultraviolet light. Bleach=bleach-containing disinfectant (10% hypochlorite). 




UV period Bleach period Bleach and period
Clostridium difficile
Exposure category 1 Quat Quat Quat Quat
Exposure category 2 Bleach Bleach Bleach Bleach
Exposure category 3* NA Quat and UV-C NA Bleach and UV-C
Exposure category 4* NA Bleach and UV-C NA Bleach and UV-C
Vegetative bacteria (MRSA, VRE, Acinetobacter spp)
Exposure category 1 Quat Quat Quat Quat
Exposure category 2 Quat Quat Bleach Bleach
Exposure category 3* NA Quat and UV-C NA Bleach and UV-C
Exposure category 4* NA Quat and UV-C NA Bleach and UV-C
Quat=quaternary ammonium-containing disinfectant. UV-C=disinfecting ultraviolet light. MRSA=meticillin-resistant 
Staphylococcus aureus. VRE=vancomycin-resistant enterococci. *Only relevant for UV study groups. 
Table 2: Differences in terminal disinfection strategies for each exposure category
of hospital-acquired C difficile, MR SA, VR E, an d 
multidrug-resistant Acinetobacter spp. Although these 
findings were not significant, they supplement the 
primary results from our BETR Disinfection study, and 
provide further validity of the benefit of using enhanced 
terminal room disinfection methods. Our findings also 
show that enhanced disinfection with UV has both a 
direct effect on the next patient who enters a contact 
isolation room,14 and an indirect beneficial effect on other 
hospitalised patients. In particular, the addition of UV to 
standard chemical disinfection led to a significant 
reduction in the hospital-wide risk of acquiring C difficile 
and VRE. 
We believe enhanced terminal room disinfection 
strategies that target high-risk rooms led to a decrease in 
hospital-wide incidence of multidrug-resistant organisms 
and C difficile th rough se veral pl ausible di rect an d 
indirect methods.
First, patients with one type of multidrug-resistant 
organism are often colonised with other multidrug-
resistant organisms.16 Thus, an intervention targeting 
one specific organism might concurrently decrease the 
risk for colonisation or infection with others.
Second, rooms of patients colonised or infected with 
one or more target organisms could serve as the 
epicentres for transmission within a hospital when 
contamination of shared equipment and health-care 
professionals’ hands and clothing occurs. The hands and 
clothing of health-care professionals regularly become 
contaminated by both the patient and the environment.17–19
Finally, our strategy of using enhanced terminal room 
disinfection strategies in targeted, contact precaution 
rooms actually led to more uses of the UV-C device than 
was required for patients qualifying for assessment of 
the primary outcome in the BETR Disinfection study.14 
We used the UV device 21 844 times during the study, yet 
only 6549 (30%) of these uses were in patients qualifying 
for the trial’s primary outcome. This discrepancy can be 
explained by the difference in criteria provided to 
environmental services for conduct of the study 
(ie, any contact precautions room) and the strict study 
definitions that led to our definition of exposed for the 
primary outcome (ie, seed rooms, which relied on 
microbiological data). This approach led to the use of 
UV-C devices in non-seed rooms in numerous different 
ways. First, more than 5000 patients admitted to seed 
rooms were excluded from the primary analysis because 
they met one of our exclusion criteria. However, our 
study protocol dictated that a UV-C device would have 
been used in these rooms. Second, numerous patients 
were routinely placed in contact precautions because of a 
remote (>12 month) history of infection or colonisation 
with one of our target multidrug-resistant organisms. 
Third, some patients were placed on contact precautions 
for other clinically important organisms (eg, norovirus, 
multidrug-resistant Gram-negative rods). Fourth, some 
patients were placed on contact precautions because they 
met criteria for syndromic surveillance. Finally, we know 
from discussions with local environmental services 
personnel that the UV-C devices were occasionally used 
by request of floor nurses. In summary, the inclusion of 
these additional rooms and the subsequent decrease in 
environmental bioburden of target organisms in contact 
precaution rooms probably contributed to our hospital-
wide outcomes.
In light of the above discussion, we believe enhanced 
room disinfection interventions that decrease the overall 
cumulative burden of baseline environmental conta-
mination in a hospital result in a secondary, indirect 
decrease in the hospital-wide incidence of hospital-
acquired multidrug-resistant organisms. For example, 
once present in a room, these pathogens might serve as 
sources for subsequent exposure to multiple patients 
sequentially admitted in the same room or adjacent rooms 
over many days and even weeks. Investigators recently 
published a metagenomic analysis20 of more than 
6000 samples from hospital surfaces, patients, and staff 
during a 12-month period surrounding the opening of a 
new hospital in Chicago. Patients routinely acquired room-
associated taxa during the first 24 h in the hospital room. 
Thus, changes that affect the hospital microbiome would 
logically affect the risk of patient exposure, particularly for 
organisms that might be part of the so-called faecal patina 
in hospitals, such as C difficile and VRE.21
The decreases in hospital-wide incidence observed in 
this study are consistent with previously published data 
on the use of UV-C devices. Authors of a meta-analysis of 
13 studies22 concluded that UV disinfection was most 
effective at decreasing incidence of hospital-acquired 
C difficile and VRE. However, all but one of these studies 
(our primary analysis study) were done in single centres 
using quasi-experimental study design, included 
multiple interventions, did not have appropriate controls, 
and did not measure compliance with hand hygiene, 
measure environmental cleaning, or account for infinite 
time bias. By contrast, our study is the first multicentre, 
randomised controlled trial to show a decrease in 
hospital-wide incidence after implemen tation of 
enhanced terminal disinfection with UV. It remains 
unclear, however, why this effect was observed in the UV 
study period but not in the bleach and UV study period. 
It is conceivable that the microfibre used in the UV study 
period, implementation issues, or both, could have 
contributed to the difference. However, we note that the 
difference between the UV study period and bleach and 
UV study period is consistent throughout our results, 
including the patient-specific outcomes, microbiological 
outcomes, and hospital-wide outcomes.
Our findings are consistent with previously published 
data that patients admitted to rooms recently vacated by 
patients with multidrug-resistant organisms are at 
increased risk of infection.13 This finding further suggests 
that patients with asymptomatic colonisation with 
multidrug-resistant organisms might serve as a source of 
environmental contamination that increases risk for 
subsequent patients admitted to hospital. Coupled with 
implementation data from our trial,23 this finding also 
underscores the challenge of providing enhanced 
terminal disinfection with UV to high-risk rooms. 
Despite casting a wide net to capture eligible rooms, we 
only used the UV machine in 60% of seed rooms (see 
categories 2 and 4 in figure 2) because of delays in 
assessment of microbiological results or missed 
opportunities. Strategies to identify colonised patients 
more rapidly, finding methods to better implement 
enhanced terminal room disinfection strategies, and 
applying these strategies more globally could help 
overcome these limitations.
Adding enhanced disinfection with UV to standard 
chemical disinfection led to a decrease in hospital-wide 
acquisition of multidrug-resistant organisms and 
C difficile, but this decrease was modest. Indeed, the 
effect of environmental disinfection on the incidence of 
C difficile in particular might be modest. Ray and 
colleagues24 recently published data from a 12-month 
randomised controlled trial involving 15 hospitals to 
investigate the effect of enhanced chemical disinfection 
with bleach on the incidence of hospital-onset C difficile 
infection.24 Despite significantly improving cleaning 
compliance with bleach, the intervention did not lead to a 
decrease in the incidence of hospital-wide hospital-onset 
C difficile. Results from our study are similar, because 
enhanced use of bleach did not decrease the hospital-
wide incidence of hospital-onset C difficile. Other 
published data also suggest that the role of the hospital 
environment on transmission of C difficile might not be 
large.25–27 Although our data provide evidence that 
disinfection does indeed have some role to play in 
prevention, findings from these studies collectively show 
that hospitals need to employ additional strategies to 
specifically affect transmission of C difficile. For example, 
hospitals should use antimicrobial stewardship teams to 
decrease the use of unnecessary antibiotics both in 
inpatient and outpatient settings, particularly by 
decreasing the use of high-risk antibiotics such as 
clindamycin and fluoroquinolones.27,28
Limitations of this study are similar to the limitations 
of our primary analysis.14 For example, we did not 
specifically screen patients for colonisation, but relied on 
cultures obtained during routine clinical practice. 
Second, we did not perform formal adjustments for 
multiple testing. Third, we did not measure antimicrobial 
use during our study. Therefore, the decrease observed 
with C difficile could be related to changes in antimicrobial 
administration during the study. This seems unlikely, 
however, given the randomised nature of the study. 
Fourth, our implementation strategies, outlined in detail 
elsewhere,23 might not be feasible in all hospital settings. 
Fifth, our study was performed in hospitals in the 
southeastern USA. Although our results included data 
from both tertiary and community hospitals, care 
provided in study settings might not be generalisable to 
all locations. Finally, our hospital-wide analyses were 
limited to four organisms and outcomes that occurred 
while the patient remained in hospital. Thus, the effects 
observed in our study might represent the minimum 
decrease achievable from enhanced disinfection 
strategies.
In conclusion, enhanced terminal room disinfection 
with UV in a targeted subset of high-risk rooms 
(ie, contact precaution rooms) led to a decrease in risk of 
acquisition of target multidrug-resistant organisms such 
as C difficile and VRE for all hospitalised patients, through 
both direct and indirect effects. These findings are 
important, because they suggest that strategies targeting 
high-risk rooms might have benefit for the larger 
population of patients admitted to hospital by reducing 
the burden of pathogenic organisms in the hospital 
microbiome. The struggle against the transmission of 
and infections from multidrug-resistant organisms and 
C difficile requires diligence, effort, and evidence-based 
strategies. Data from our study should help expand our 
understanding of the importance of disinfection practices 
in the hospital setting.
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